Evaluation of the Efficacy of Transcranial Magnetic Stimulation on Resistant Auditory Hallucinations in Schizophrenia
Launched by DOMINIQUE JANUEL · Sep 12, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a treatment called transcranial magnetic stimulation (TMS) on patients with schizophrenia who experience persistent auditory hallucinations, which are sounds or voices that aren't really there. The goal is to see if TMS can help reduce these challenging symptoms when used alongside standard medication. There are two different methods of TMS being tested, and researchers will measure how well they work by using a specific scale that assesses the severity of these hallucinations.
To be eligible for this trial, participants must be at least 18 years old, diagnosed with schizophrenia, and have tried at least two different medications without success in treating their hallucinations. It's important that participants can communicate in French and agree to take part in the study. Those who decide to join can expect to receive TMS treatment and attend regular evaluations to track their progress. Participants should also be aware that individuals with certain medical conditions or who are pregnant may not be able to join for safety reasons.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient over 18 years of age
- • Patient diagnosed with schizophrenia according to DSM-V criteria (Diagnostic and Statistical Manual of Mental Disorder V5, 2013)
- • Presence of auditory hallucinations: Resistant auditory hallucinations: resistance to treatment with 2 different well-conducted antipsychotics.
- • Patient agreeing to participate in the study and having signed an informed consent
- • Patient with French language skills
- • Affiliation to a social security system
- • Women of childbearing age must be on contraception and have a negative pregnancy test (βHCG)
- Exclusion Criteria:
- • Have a contraindication to MST: intracranial foreign body, unstabilized epilepsy, cochlear implant
- • Presence of an unstabilized medical condition
- • Pregnant woman (Women of childbearing age without effective contraception)
- • Current or less than one month old engagement in another research protocol
- • A person who is subject to a safeguard of justice measure
- • An adult under curatorship
- • Minor patients with mental health problems
- • Pregnant or breastfeeding women
- • A person in a social fragility (Persons deprived of liberty by a judicial or administrative decision, hospitalized persons)
- • Persons incapable or unable to give consent
About Dominique Januel
Dominique Januel is a dedicated clinical trial sponsor specializing in the design and execution of innovative research studies aimed at advancing medical knowledge and improving patient outcomes. With a strong focus on collaboration and integrity, Dominique Januel leads a team of experienced professionals committed to adhering to the highest ethical standards and regulatory guidelines. The organization emphasizes rigorous scientific methodology and data integrity, ensuring that all trials are conducted efficiently and transparently. By fostering partnerships with healthcare providers and research institutions, Dominique Januel aims to facilitate groundbreaking discoveries that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Neuilly Sur Marne, , France
Patients applied
Trial Officials
Dominique JANUEL
Study Director
Clinical research unit, EPS Ville Evrard
Noomane BOUAZIZ
Principal Investigator
Clinical research unit, EPS Ville Evrard
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported